CPT® Code 79200

1. Indications

Radiopharmaceutical therapy by intracavitary administration is indicated for the treatment of specific diseases or conditions that require targeted radiation therapy. The following are the primary indications for this procedure:

• Treatment of Cancer This therapy is often utilized in the management of various types of cancer, where localized radiation can effectively target tumor cells while sparing surrounding healthy tissue.
• Palliative Care It may also be indicated for palliative treatment, providing relief from symptoms associated with advanced cancer or other debilitating conditions.

2. Procedure

The procedure for radiopharmaceutical therapy by intracavitary administration involves several critical steps to ensure effective treatment delivery. Each step is designed to maximize the therapeutic benefits while minimizing risks to the patient.

• Step 1: Patient Preparation Prior to the procedure, the patient undergoes a thorough evaluation, including imaging studies and assessments to determine the appropriate site for radioisotope placement. Informed consent is obtained, and the patient is educated about the procedure, potential risks, and expected outcomes.
• Step 2: Device Placement If surgical placement of a device is required, the patient is taken to the operating room. Under sterile conditions and local or general anesthesia, a catheter or other delivery device is surgically inserted into the targeted area. This device is designed to hold the radioisotope securely in place during the treatment period.
• Step 3: Radioisotope Administration Once the device is in place, the dose-specific radioisotope is loaded into the device. The administration is performed under strict safety protocols to protect healthcare personnel and the patient from unnecessary radiation exposure.
• Step 4: Monitoring After the radioisotope is administered, the patient is monitored for any immediate reactions or complications. Depending on the duration of therapy, the patient may remain in the facility for observation or be discharged with specific instructions.
• Step 5: Device Removal After the specified duration of therapy, the device containing the radioisotope is carefully removed. This step is performed in a controlled environment to ensure safety and compliance with radiation safety standards.

3. Post-Procedure

Post-procedure care for patients who have undergone radiopharmaceutical therapy by intracavitary administration includes monitoring for any adverse effects related to the treatment. Patients may experience localized discomfort or other side effects, which should be managed appropriately. Follow-up appointments are essential to assess the treatment's effectiveness and to monitor for any potential complications. Patients are also provided with specific instructions regarding activity restrictions, hygiene, and any necessary precautions to minimize radiation exposure to others during the recovery period.